Renal Cell Carcinoma | Unmet Need | Detailed, Expanded Analysis: Metastatic Renal Cell Carcinoma

Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival delivered by these therapies have only been incremental. Consequently, high unmet need still remains in the disease, and there is significant clinical and commercial opportunity for drug developers with new therapies that can extend patients' lives compared to the current standard of care. This report provides an in-depth analysis of unmet need, examines the key drivers of prescribing behavior, and provides analysis of significant commercial opportunities for metastatic renal cell carcinoma.

Report Details

- Pub Date: April 2016
- Author(s): Paul Wilcock. PhD